The title compounds, C7H4I2O2 1 and C13H7I2N2O3 2, have been synthesized and characterized by single-crystal X-ray diffraction. Compound 1 crystallizes in monoclinic, space group P21/c with a = 9.802（2）, b = 13.867（3）, c = 7.364（2） A, β = 109.74（3）°, V= 942.1（3） A^3, Dc= 2.636 g/cm^3, C7H4I2O2, Mr= 373.90, F（000） = 672, μ = 6.627 mm^-1, Z = 4, R = 0.0459 and wR = 0.1018 for 1805 observed reflections （I 〉 2 σ（I））. Compound 2 belongs to the monoclinic system, space group P21/n with a = 9.015（2）, b = 12.024（2）, c = 14.072（3） A, β = 103.91（3）°, V = 1480.6（5） A^3, Dc= 2.216 g/cm^3, C13H7I2N2O3, Mr= 494.01, F（000） = 920, p = 4.255 mm^-1, Z = 4, R = 0.0777 and wR = 0.1757 for 2896 observed reflections （I 〉 2σ（I））. Compounds 1 and 2 were assayed for antibacterial activities against three Gram positive bacterial strains （B. subtilis, S. aureus and S. faecalis） and three Gram negative bacterial strains （E. coli, P. aeruginosa and E. cloacae） by MTr method. Fortunately, compound 2 is found to show potent antibacterial activity against these six bacterial strains.
2,4-Diiodo-6-[（2-morpholin-4-yl-ethylimino）-methyl]-phenol-copper（Ⅱ） has been designed and synthesized.The structure was determined by UV,IR and single-crystal X-ray study.The title complex crystallizes in the triclinic system,space group P1 with a=6.6090（13）,b=10.377（2）,c=12.550（3）A,α=113.29（3）,β=93.84（3）,γ=98.31（3）°,V=774.9（3）A^3,Dc=2.215g/cm^3,C26H30CuO4N4I4,Mr=1033.68,F（000）=487,μ=4.726 mm^-1,Z=1,the final R=0.0563 and wR=0.1475 for 2101 observed reflections（I〉2σ（I））.The central copper（Ⅱ） is four-coordinated by two nitrogen atoms and two oxygen atoms from two 3,5-diiodosalicylaldehyde-2-morpholinoethylamine Schiff bases.The complex is linked into a column by π-π stacking interaction.The complex was assayed for antibacterial activities against three Gram positive bacterial strains（B.subtilis,S.aureus and S.faecalis） and three Gram negative bacterial strains（E.coli,P.aeruginosa and E.cloacae） by MTT method.Fortunately,the title complex shows potent antibacterial activity against these six bacterial strains.
One dinuclear complex [Cu2Cl2（HEMDP） 2]·THF 1（H2EMDP = 2-[（2-hydroxyethylimino）-methyl]-4,6-diiodo-phenol,THF = tetrahydrofuran） has been designed and synthesized by H2EMDP with CuCl2·2H2O in THF solvent. Complex 1 was characterized by UV,IR,ESI-MS,and elemental analyses. 1 was characterized by X-ray crystallography. The crystal belongs to the monoclinic system,space group C2/c with a = 27.886（3） ,b = 8.6890（12） ,c = 26.698（2）A,β = 105.521（2） o,V = 6233.1（12）A^3,Z = 8,Mr = 1102.01,μ = 5.533 mm^-1,Dc = 2.349 Mg/m^3,F（000） = 4112,the final R = 0.0486 and wR = 0.1175（I 〉 2σ（I）） . In addition,further investigation revealed that the central copper（Ⅱ） atom in the complex is five-coordinated by one nitrogen atom and two oxygen atoms from H2EMDP and two chlorine atoms from chlorid. The 3,5-diiodosalicylaldehyde Schiff base acts as a tridentate ligand. H2EMDP and 1 were assayed for antibacterial（B. subtilis,S. aureus,S. faecalis,P. aeruginosa,E. coli and E. cloacae） activities by MTT（3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyl trtrazolium bromide） method. 1 showed the most favorable antimicrobial activity with MICs of 3.125,6.25,6.25,12.5,3.125 and 6.25 μg/mL against B. subtilis,S. aureus,S. faecalis,P. aeruginosa,E. coli and E.cloacae,respectively.
